• About
  • Blog
  1. Home
  2. Blog
  3. Companies
  4. DXCM

DexCom, Inc.(DXCM)

NASDAQ Global Select
Sector: Healthcare | Industry: Medical - Devices
DexCom, Inc. logo

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Latest News & Analysis

Glucose monitor device on sleek desk with blurred purple-toned background
Jul 29, 2025

DexCom Inc. (DXCM) Market Analysis: AI Integration, Stelo Launch & Regulatory Challenges

DexCom's AI-driven innovation and Stelo OTC launch shape its market position amid regulatory hurdles and evolving diabetes care trends.

Read more →
DexCom's AI-powered continuous glucose monitoring (CGM) device, with its strategic OTC expansion, transforming diabetes management and driving financial growth.
Jul 28, 2025

DexCom, Inc. Market Analysis: AI Innovation, Stelo OTC Launch & Financial Growth Insights

Explore DexCom's AI-driven CGM advancements, Stelo OTC launch, robust financials, and governance considerations shaping its competitive edge and investor outlook.

Read more →
Wearable glucose monitor beside healthy meals on a sleek table with a soft purple kitchen background
Jul 28, 2025

DexCom, Inc. Market Analysis: Strategic AI Innovation and Financial Performance Insights

Analyze DexCom's latest AI-driven CGM advancements, financial metrics, and market positioning to understand strategic growth and investor implications.

Read more →
Group of business professionals analyzing charts at a glass conference table with a purple gradient background
Jul 18, 2025

DexCom, Inc. Market Update: Navigating Legal Challenges Amid Strong Financial Growth

DexCom faces shareholder lawsuits amid strong revenue growth and innovation leadership, balancing legal risks with promising financial outlook.

Read more →
Medical device with digital screen on a glass table in a modern office with purple lighting
Jul 14, 2025

DexCom, Inc. (DXCM) Latest Market Analysis: Growth, Regulatory Challenges, and Strategic Positioning

Comprehensive analysis of DexCom's Q2 earnings outlook, Medicare reimbursement impact, legal issues, and competitive stance in the CGM market.

Read more →
Elderly person using a medical device while seated in a clinic with healthcare staff in a purple-themed setting
Jul 10, 2025

DexCom Inc. Analysis: Shareholder Investigation, Regulatory Challenges, and Financial Resilience

DexCom faces shareholder lawsuits, Medicare cuts, and FDA scrutiny amid strong financial growth and innovation. Insights on Q2 earnings and strategic outlook.

Read more →
Businesswoman checks financial charts on a tablet in a modern office with a purple-themed cityscape background
Jul 2, 2025

DexCom Q2 2025 Earnings Analysis: Navigating Reimbursement Risks and Market Competition

DexCom's Q2 2025 earnings reveal resilience amid reimbursement policy risks, shareholder lawsuits, and competitive pressures in the CGM market.

Read more →
Business professional studies financial charts in a sleek office with abstract purple decor
Jul 1, 2025

DexCom Inc. (DXCM) Market Analysis: Navigating Medicare Cuts and Strategic Growth

DexCom faces Medicare reimbursement challenges and shareholder scrutiny while leveraging G7 innovation and expanding market reach. A detailed financial and strategic analysis.

Read more →
Businesswoman at modern office desk with abstract purple graphs in the background
Jun 27, 2025

DexCom (DXCM): Navigating Legal Headwinds and Strategic Shifts

DexCom navigates legal challenges and FDA scrutiny while its G7 sensor drives revenue growth, reshaping its market position and investor outlook.

Read more →
Business professionals meeting at a conference table with digital financial charts in the background
Jun 25, 2025

DexCom (DXCM): Growth, Lawsuits, and CGM Market Dominance Explained

DexCom (DXCM) expands into Type 2 diabetes amidst strong market share, but faces shareholder lawsuits and margin pressures. Unpack its financial health and strategic outlook.

Read more →
Medical device on a sleek table with digital graphs and healthcare icons in a soft purple background
Jun 16, 2025

DexCom (DXCM) Navigates Growth Amid Legal & Competitive Headwinds

DexCom navigates strong Q1 2025 revenue growth amid legal scrutiny and competitive shifts, driven by strategic leadership and aging demographics.

Read more →
Wearable glucose monitor on reflective surface with abstract medical icons and a purple-themed background
Jun 12, 2025

DexCom (DXCM) Navigates Innovation Amid Legal Scrutiny

DexCom navigates legal scrutiny and product innovation, launching its G7 15-day sensor while maintaining strong financial growth and market leadership in CGM technology.

Read more →
DexCom (DXCM) stock analysis: Balancing legal investigations and G7 continuous glucose monitoring (CGM) system innovation, influencing market performance and future growth in diabetes technology.
Jun 11, 2025

DexCom DXCM: Legal Scrutiny Meets G7 Innovation in Mid-2025

DexCom navigates legal challenges and product launches, including the G7, impacting its market position and investor sentiment in mid-2025.

Read more →
Dexcom G7 CGM system: FDA approved continuous glucose monitoring technology for diabetes management.
Apr 21, 2025

DexCom (DXCM): G7 FDA Clearance Amid Shareholder Investigations

DexCom (DXCM) balances the strategic boost from its G7 15-day CGM FDA clearance with the impact of ongoing shareholder investigations.

Read more →
DexCom (DXCM) stock analysis: FDA scrutiny, Nanowear partnership, and market expansion impact investor strategy. Financials from Monexa AI.
Apr 9, 2025

DexCom (DXCM): FDA Warning, Nanowear Partnership, and Market Expansion

DexCom (DXCM) faces FDA scrutiny, partners with Nanowear, and expands CGM coverage. A comprehensive look at recent developments and their impact on investors.

Read more →
DexCom's Type 2 Diabetes Strategy: Navigating FDA hurdles and competition with CGM innovation. Revenue and growth analysis included.
Mar 24, 2025

DexCom (DXCM): Navigating FDA Scrutiny, Type 2 Diabetes Market, and Competitive Landscape

DexCom (DXCM) navigates FDA scrutiny, targets Type 2 diabetes market amid CGM competition. Key developments and financial analysis included.

Read more →
DexCom (DXCM) stock analysis: CGM market growth, regulatory hurdles, and financial performance insights for investors.
Mar 20, 2025

DexCom (DXCM): FDA Hurdles, European Expansion, CGM Innovation

DexCom (DXCM) navigates FDA hurdles, expands in Europe, and innovates CGM technology. Analysis of financial performance, market dynamics, and strategic initiatives.

Read more →
Dexcom (DXCM) stock analysis: FDA warning letter, market competition, and future growth prospects in the CGM landscape.
Mar 17, 2025

DexCom (DXCM): Navigating Regulatory Scrutiny and Market Competition

DexCom faces FDA scrutiny amid CGM market competition. Analysis of regulatory challenges, competitive landscape, and financial resilience.

Read more →
DexCom stock analysis: Navigating FDA scrutiny, competition, and growth opportunities in the CGM market. Stay informed on DXCM.
Mar 11, 2025

DexCom (DXCM): FDA Warning, Competition, and Market Outlook

Analysis of DexCom's challenges and opportunities in the CGM market, including an FDA warning letter, competitive pressures, and growth prospects.

Read more →
Dexcom FDA Warning Letter: Impact on DXCM stock and CGM market competition with Abbott, plus AI integration and revenue growth analysis.
Mar 10, 2025

DexCom Under Scrutiny: FDA Warning Letter, Market Impact, Growth

DexCom (DXCM) faces FDA scrutiny, market impact, and strategic growth in diabetes care. Gain insights into their response, competition, and AI integration.

Read more →
DexCom stock analysis: Recent developments, market trends, and strategic initiatives impacting DXCM, continuous glucose monitoring systems and diabetes management solutions.
Mar 3, 2025

DexCom, Inc. - Industry Impact and Market Trends Analysis

DexCom, Inc. navigates a dynamic healthcare landscape with AI-driven CGM technology. Revenue growth faces margin pressures amid competition and market volatility.

Read more →
DexCom (DXCM) Q4 2024 Analysis: Stelo Launch, AI Integration, and Future CGM Growth
Feb 28, 2025

DexCom (DXCM): Q4 Performance, Stelo Launch, and the Future of CGM

DexCom's Q4 results show revenue growth but an earnings miss. Stelo's launch and AI integration are key. Analyst sentiment is cautiously optimistic amid competition.

Read more →
DexCom (DXCM) stock analysis: CGM market trends, Stelo OTC launch, AI integration, and DexCom's future growth strategies.
Feb 26, 2025

DexCom (DXCM) Analysis: CGM Market, Stelo Launch, and Future Growth

DexCom (DXCM) navigates the competitive CGM market with mixed Q4 results, focusing on innovation and strategic partnerships for future growth. Stelo OTC CGM launch is key.

Read more →
DexCom CGM: Understand competition, innovation, and future prospects in the CGM market. Analyst insights, financial health, and market trends.
Feb 25, 2025

DexCom (DXCM): Navigating Competition and Innovation

A comprehensive analysis of DexCom (DXCM), covering Q4 2024 performance, competition, GLP-1 impacts, AI, global expansion, and analyst views. Key takeaways for investors and analysts.

Read more →
DexCom's CGM market position: Q4 2024 earnings analysis, revenue growth, and technological innovation in diabetes management. #CGM #DexCom #DiabetesTech
Feb 21, 2025

DexCom CGM Market Analysis: Growth, Competition, and Innovation (DXCM)

DexCom (DXCM) Q4 2024 saw +8.00% revenue growth with an EPS miss amid competitive pressures and global expansion. Cautious optimism drives future strategies.

Read more →
Dexcom G7 CGM system analysis: review, financial performance, and market position. Continuous glucose monitoring technology.
Feb 21, 2025

Dexcom Q4 2024 Earnings: Analyzing CGM Market Trends

Dexcom's Q4 2024 performance shows revenue growth but an EPS miss. This report analyzes the CGM market trends, competition, and strategic initiatives.

Read more →
Close-up of a continuous glucose monitor on a person's arm in a medical setting.
Feb 18, 2025

Dexcom Q4 2024: Revenue Up, Earnings Down, What's Next?

An in-depth analysis reveals Dexcom's Q4 2024 revenue growth, earnings challenges, competitive pressures, and strategic innovation.

Read more →

Professional-grade financial analysis tools for informed investment decisions.

Product

  • Features
  • Pricing

Resources

  • Blog
  • Knowledge Base
  • Community
  • Market Data

Company

  • About
  • Careers
  • Contact
  • Partners

Legal

  • Privacy
  • Terms
  • License
  • Security

© 2025 Monexa. All rights reserved. Market data provided by financial exchanges and may be delayed as specified by financial exchanges or our data providers.